Production (Stage)
Cartesian Therapeutics, Inc.
RNAC
$10.45
$0.131.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.83% | 94.23% | -168.64% | 221.51% | -162.31% |
| Total Depreciation and Amortization | 531.69% | 78.68% | 51.32% | 11.36% | -11.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.88% | -102.58% | 3,300.82% | 280.27% | 564.22% |
| Change in Net Operating Assets | -11.19% | 275.12% | 76,008.82% | -1,068.25% | -213.69% |
| Cash from Operations | -45.18% | 69.93% | 248.57% | -45.99% | -81.60% |
| Capital Expenditure | -78.57% | -1,001.56% | -- | -13,125.00% | -363.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -78.57% | -105.45% | -- | -13,125.00% | -102.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.96% | -- | 151,721.95% | -- | 1,934.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 98.93% | -- | -- | -- |
| Cash from Financing | -118.65% | -94.44% | 602.21% | 104.64% | 28,779.87% |
| Foreign Exchange rate Adjustments | 740.00% | -193.75% | 25.00% | 150.00% | 76.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -221.39% | -144.73% | 487.88% | -26.98% | 36.02% |